*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2024 | Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons PloS one · preclinical | PMID 38656972 |
| 2013 | Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial Lancet (London, England) · preclinical | PMID 23561987 |
| 2013 | Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat Pharmacology, biochemistry, and behavior · preclinical | PMID 23932919 |
| 2010 | Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · preclinical | PMID 20200509 |
| 2010 | Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users Clinical pharmacology and therapeutics · human | PMID 20520602 |
| 2009 | Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity Current opinion in investigational drugs (London, England : 2000) · preclinical | PMID 19777399 |
| 2009 | Tesofensine and weight loss Lancet (London, England) · preclinical | PMID 19249626 |
| 2009 | Tesofensine and weight loss Lancet (London, England) · preclinical | PMID 19249625 |
| 2009 | A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam Clinical pharmacokinetics · human | PMID 19705923 |
| 2008 | Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease Obesity (Silver Spring, Md.) · preclinical | PMID 18356831 |
Tesofensine (Tesofensine (triple monoamine reuptake inhibitor)). Small molecule (not a peptide) — inhibits reuptake of noradrenaline, dopamine, and serotonin; investigated for obesity via appetite suppression. Included because it is widely co-marketed with weight-loss peptides.
Commonly discussed uses: investigational obesity research. There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Small molecule (not a peptide) — inhibits reuptake of noradrenaline, dopamine, and serotonin; investigated for obesity via appetite suppression. Included because it is widely co-marketed with weight-loss peptides.
Reported considerations: increased heart rate/blood pressure, insomnia, mood changes, dry mouth. There is both human and animal/preclinical research, though the depth and quality vary by indication. Investigational small molecule (not a peptide). Not approved. Cardiovascular/mood risk profile. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 0.25mg/day (trials), typical 0.5mg/day (trial dose), high 1mg/day (higher CV/mood risk). Administration: oral. Half-life: ~9 days (long).
Australian status: Investigational — not approved. Investigational small molecule (not a peptide). Not approved. Cardiovascular/mood risk profile. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: oral — no reconstitution; storage: room temp per product.
Commonly discussed combinations (anecdotal for unapproved compounds): investigational monotherapy; not for self-stacking. Stacking increases interaction/safety uncertainty.